Understanding Carbimazole and Its Mechanism of Action

Carbimazole is a medication used to manage thyrotoxicosis, a condition characterized by an overactive thyroid gland. It is typically administered in high doses for six weeks until the patient becomes euthyroid, or has a normal thyroid function. The drug works by blocking thyroid peroxidase, an enzyme responsible for coupling and iodinating the tyrosine residues on thyroglobulin, which ultimately reduces thyroid hormone production.

In contrast to propylthiouracil, another medication used to treat thyrotoxicosis, carbimazole only has a central mechanism of action. Propylthiouracil, on the other hand, also has a peripheral action by inhibiting 5′-deiodinase, an enzyme that reduces peripheral conversion of T4 to T3.

While carbimazole can be effective in managing thyrotoxicosis, it is not without its adverse effects. One of the most serious side effects is agranulocytosis, a condition characterized by a severe reduction in white blood cells. Additionally, carbimazole can cross the placenta, but may be used in low doses during pregnancy.

Overall, carbimazole is a medication that can be effective in managing thyrotoxicosis, but it is important to be aware of its mechanism of action and potential adverse effects. Patients should always consult with their healthcare provider before starting any new medication.

Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Counselling for Women Considering the Combined Oral Contraceptive Pill

Women who are considering taking the combined oral contraceptive pill (COC) should receive counselling on the potential harms and benefits of the pill. The COC is highly effective if taken correctly, with a success rate of over 99%. However, there is a small risk of blood clots, heart attacks, and strokes, as well as an increased risk of breast and cervical cancer.

In addition to discussing the potential risks and benefits, women should also receive advice on how to take the pill. If the COC is started within the first 5 days of the menstrual cycle, there is no need for additional contraception. However, if it is started at any other point in the cycle, alternative contraception should be used for the first 7 days. Women should take the pill at the same time every day and should be aware that intercourse during the pill-free period is only safe if the next pack is started on time.

There have been recent changes to the guidelines for taking the COC. While it was previously recommended to take the pill for 21 days and then stop for 7 days to mimic menstruation, it is now recommended to discuss tailored regimes with women. This is because there is no medical benefit to having a withdrawal bleed, and options include never having a pill-free interval or taking three 21-day packs back-to-back before having a 4 or 7 day break.

Women should also be informed of situations where the efficacy of the pill may be reduced, such as vomiting within 2 hours of taking the pill, medication that induces diarrhoea or vomiting, or taking liver enzyme-inducing drugs. It is also important to discuss sexually transmitted infections and precautions that should be taken with enzyme-inducing antibiotics such as rifampicin.

Overall, counselling for women considering the COC should cover a range of topics to ensure that they are fully informed and able to make an informed decision about their contraceptive options.

Sildenafil is frequently prescribed in primary care. Adverse effects of sildenafil consist of headaches, facial flushing, indigestion, and temporary visual disturbances with a blue-green tint.

Understanding Phosphodiesterase Type V Inhibitors

Phosphodiesterase type V (PDE5) inhibitors are medications used to treat erectile dysfunction and pulmonary hypertension. These drugs work by increasing the levels of cGMP, which leads to the relaxation of smooth muscles in the blood vessels supplying the corpus cavernosum. The most well-known PDE5 inhibitor is sildenafil, also known as Viagra, which was the first drug of its kind. It is a short-acting medication that is usually taken one hour before sexual activity.

Other PDE5 inhibitors include tadalafil (Cialis) and vardenafil (Levitra). Tadalafil is longer-acting than sildenafil and can be taken on a regular basis, while vardenafil has a similar duration of action to sildenafil. However, these drugs are not suitable for everyone. Patients taking nitrates or related drugs, those with hypotension, and those who have had a recent stroke or myocardial infarction should not take PDE5 inhibitors.

Like all medications, PDE5 inhibitors can cause side effects. These may include visual disturbances, blue discolouration, non-arteritic anterior ischaemic neuropathy, nasal congestion, flushing, gastrointestinal side-effects, headache, and priapism. It is important to speak to a healthcare professional before taking any medication to ensure that it is safe and appropriate for you.

Overall, PDE5 inhibitors are an effective treatment for erectile dysfunction and pulmonary hypertension. However, they should only be used under the guidance of a healthcare professional and with careful consideration of the potential risks and benefits.

Antiretroviral therapy (ART) for HIV involves a combination of at least three drugs, typically two nucleoside reverse transcriptase inhibitors (NRTI) and either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). Entry inhibitors, NRTIs, NNRTIs, PIs, and integrase inhibitors are all used to manage HIV. The 2015 BHIVA guidelines recommend starting ART as soon as a patient is diagnosed with HIV. Each drug has its own side effects, and some of the common ones include peripheral neuropathy, renal impairment, osteoporosis, diabetes, hyperlipidemia, and P450 enzyme interaction.

Due to her positive family history, smoking, and excess alcohol intake, this woman is at a higher risk of developing osteoporosis. Therefore, it is recommended that she undergo a FRAX assessment without delay, rather than waiting until the age of 65 as typically recommended for women without such risk factors.

Assessing the Risk of Osteoporosis

Osteoporosis is a concern due to the increased risk of fragility fractures. To determine which patients require further investigation, NICE produced guidelines in 2012 for assessing the risk of fragility fracture. Women aged 65 years and older and men aged 75 years and older should be assessed, while younger patients should be assessed in the presence of risk factors such as previous fragility fracture, history of falls, and low body mass index.

NICE recommends using a clinical prediction tool such as FRAX or QFracture to assess a patient’s 10-year risk of developing a fracture. FRAX estimates the 10-year risk of fragility fracture and is valid for patients aged 40-90 years. QFracture estimates the 10-year risk of fragility fracture and includes a larger group of risk factors.

If the FRAX assessment was done without a bone mineral density (BMD) measurement, the results will be categorised into low, intermediate, or high risk. If the FRAX assessment was done with a BMD measurement, the results will be categorised into reassurance, consider treatment, or strongly recommend treatment. Patients assessed using QFracture are not automatically categorised into low, intermediate, or high risk.

NICE recommends reassessing a patient’s risk if the original calculated risk was in the region of the intervention threshold for a proposed treatment and only after a minimum of 2 years or when there has been a change in the person’s risk factors.

If a patient is taking aminosalicylates, they may experience various haematological adverse effects, such as agranulocytosis. Therefore, it is crucial to conduct a full blood count promptly if the patient presents with symptoms like fever, fatigue, bleeding gums, or a sore throat to rule out agranulocytosis. While C-reactive protein may be a part of the overall management plan, it is not the most critical initial investigation and is unlikely to alter the management plan. Similarly, while a throat swab may be necessary, it is not the most crucial initial investigation. The monospot test for glandular fever may be useful if glandular fever is suspected, but it is not the most important initial investigation.

Aminosalicylate drugs, such as 5-aminosalicyclic acid (5-ASA), are released in the colon and act locally as anti-inflammatories. The exact mechanism of action is not fully understood, but it is believed that 5-ASA may inhibit prostaglandin synthesis. Sulphasalazine is a combination of sulphapyridine and 5-ASA, but many of its side-effects are due to the sulphapyridine component, including rashes, oligospermia, headache, Heinz body anaemia, megaloblastic anaemia, and lung fibrosis. Other side-effects are common to 5-ASA drugs, such as mesalazine, which is a delayed release form of 5-ASA that avoids the sulphapyridine side-effects seen in patients taking sulphasalazine. However, mesalazine is still associated with side-effects such as gastrointestinal upset, headache, agranulocytosis, pancreatitis, and interstitial nephritis. Olsalazine is another aminosalicylate drug that consists of two molecules of 5-ASA linked by a diazo bond, which is broken by colonic bacteria.

It is important to note that aminosalicylates are associated with various haematological adverse effects, including agranulocytosis, and a full blood count (FBC) is a key investigation in an unwell patient taking them. Additionally, pancreatitis is seven times more common in patients taking mesalazine than in those taking sulfasalazine.

Complications of Myocardial Infarction

Myocardial infarction (MI) can lead to various complications, which can occur immediately, early, or late after the event. Cardiac arrest is the most common cause of death following MI, usually due to ventricular fibrillation. Patients are treated with defibrillation as per the ALS protocol. Cardiogenic shock may occur if a significant portion of the ventricular myocardium is damaged, leading to a decrease in ejection fraction. This condition is challenging to treat and may require inotropic support and/or an intra-aortic balloon pump. Chronic heart failure may develop if the patient survives the acute phase, and loop diuretics such as furosemide can help decrease fluid overload. Tachyarrhythmias, such as ventricular fibrillation and ventricular tachycardia, are common complications of MI. Bradyarrhythmias, such as atrioventricular block, are more common following inferior MI.

Pericarditis is a common complication of MI in the first 48 hours, characterized by typical pericarditis pain, a pericardial rub, and a pericardial effusion. Dressler’s syndrome, which occurs 2-6 weeks after MI, is an autoimmune reaction against antigenic proteins formed during myocardial recovery. It is treated with NSAIDs. Left ventricular aneurysm may form due to weakened myocardium, leading to persistent ST elevation and left ventricular failure. Patients are anticoagulated due to the increased risk of thrombus formation and stroke. Left ventricular free wall rupture and ventricular septal defect are rare but serious complications that require urgent surgical correction. Acute mitral regurgitation may occur due to ischaemia or rupture of the papillary muscle, leading to acute hypotension and pulmonary oedema. Vasodilator therapy and emergency surgical repair may be necessary.

If a patient experiences cardiac arrest in VF/pulseless VT and is monitored, such as in a coronary care unit, critical care unit, or catheter laboratory, they should receive a maximum of three successive shocks instead of one shock followed by two minutes of CPR. After the shocks, chest compressions should be administered for two minutes. Once compressions restart, adrenaline 1mg IV and amiodarone 300 mg IV should be given for shockable rhythms (VT/pulseless VF). Adrenaline 1mg IV should be given after alternate shocks (every 3-5 minutes). For non-shockable rhythms (pulseless electrical activity/asystole), adrenaline 1mg IV should be given as soon as venous access is achieved and administered alongside CPR. Pulseless electrical activity is a type of cardiac arrest where there is electrical activity (other than ventricular tachycardia) that would normally have an associated pulse. Asystole is a complete cessation of any electrical and mechanical heart activity.

The 2015 Resus Council guidelines for adult advanced life support outline the steps to be taken when dealing with patients with shockable and non-shockable rhythms. For both types of patients, chest compressions are a crucial part of the process, with a ratio of 30 compressions to 2 ventilations. Defibrillation is recommended for shockable rhythms, with a single shock for VF/pulseless VT followed by 2 minutes of CPR. Adrenaline and amiodarone are the drugs of choice for non-shockable rhythms, with adrenaline given as soon as possible and amiodarone administered after 3 shocks for VF/pulseless VT. Thrombolytic drugs should be considered if a pulmonary embolus is suspected. Atropine is no longer recommended for routine use in asystole or PEA. Oxygen should be titrated to achieve saturations of 94-98% following successful resuscitation. The Hs and Ts should be considered as potential reversible causes of cardiac arrest.

Dietary Recommendations for Type II Diabetes Management

Managing type II diabetes requires a comprehensive approach that includes lifestyle modifications and medication. One crucial aspect of diabetes management is a healthy, balanced diet. The National Institute for Health and Care Excellence (NICE) provides guidelines on dietary recommendations for people with type II diabetes.

Low-fat dairy and oily fish are recommended to control the intake of saturated and trans fatty acids. Oily fish contains Omega-3 fatty acids, which are cardio-protective. High-fibre foods with carbohydrates with a low glycaemic index, such as fruits, vegetables, whole grains, and pulses, are also recommended.

Sucrose-containing foods should be limited, and care should be taken to avoid excess energy intake. NICE discourages the use of foods marketed specifically for people with type II diabetes, as they are often higher in calories.

Weight loss is an essential aspect of diabetes management, particularly for overweight individuals. NICE recommends a weight loss target of 5-10% for overweight adults with type II diabetes. Those who achieve a weight loss of 10% or more in the first five years after diagnosis have the greatest chance of seeing their disease go into remission.

In summary, a healthy, balanced diet that includes low-fat dairy, oily fish, high-fibre foods with low glycaemic index carbohydrates, and limited sucrose-containing foods is crucial for managing type II diabetes. Weight loss is also an essential aspect of diabetes management, particularly for overweight individuals.

Treatment Options for Latent Tuberculosis

Latent tuberculosis is a disease that can remain dormant in the body for years without causing any symptoms. However, if left untreated, it can develop into active tuberculosis, which can be life-threatening. To prevent this from happening, NICE now offers two choices for treating latent tuberculosis.

The first option is a combination of isoniazid (with pyridoxine) and rifampicin for three months. This is recommended for people under the age of 35 who are concerned about the hepatotoxicity of the drugs. Before starting this treatment, a liver function test is conducted to assess the risk factors.

The second option is a six-month course of isoniazid (with pyridoxine) for people who are at risk of interactions with rifamycins. This includes individuals with HIV or those who have had a transplant. The risk factors for developing active tuberculosis include silicosis, chronic renal failure, HIV positivity, solid organ transplantation with immunosuppression, intravenous drug use, haematological malignancy, anti-TNF treatment, and previous gastrectomy.

In summary, the choice of treatment for latent tuberculosis depends on the individual’s clinical circumstances and risk factors. It is important to consult with a healthcare professional to determine the best course of action.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Postpartum haemorrhage caused by uterine atony can be treated with various medical options such as oxytocin, ergometrine, carboprost and misoprostol.

Uterine atony is the primary cause of postpartum haemorrhage, which occurs when the uterus fails to contract fully after the delivery of the placenta, leading to difficulty in achieving haemostasis. This condition is often associated with overdistension, which can be caused by multiple gestation, macrosomia, polyhydramnios or other factors.

In addition to the standard approach for managing PPH, including an ABC approach for unstable patients, the following steps should be taken in sequence:

1. Bimanual uterine compression to stimulate contraction manually
2. Intravenous oxytocin and/or ergometrine
3. Intramuscular carboprost
4. Intramyometrial carboprost
5. Rectal misoprostol
6. Surgical intervention such as balloon tamponade

(RCOG Green-top Guideline No. 52)

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Adrenaline can be administered every 5 minutes in the management of anaphylaxis. It is recommended that individuals with a history of anaphylaxis carry two auto-injectors with them in case a second dose is needed.

Anaphylaxis is a severe and potentially life-threatening allergic reaction that affects the entire body. It can be caused by various triggers, including food, drugs, and insect venom. The symptoms of anaphylaxis typically occur suddenly and progress rapidly, affecting the airway, breathing, and circulation. Common signs include swelling of the throat and tongue, hoarse voice, respiratory wheeze, dyspnea, hypotension, and tachycardia. In addition, around 80-90% of patients experience skin and mucosal changes, such as generalized pruritus, erythematous rash, or urticaria.

The management of anaphylaxis requires prompt and decisive action, as it is a medical emergency. The Resuscitation Council guidelines recommend intramuscular adrenaline as the most important drug for treating anaphylaxis. The recommended doses of adrenaline vary depending on the patient’s age, ranging from 100-150 micrograms for infants under 6 months to 500 micrograms for adults and children over 12 years. Adrenaline can be repeated every 5 minutes if necessary, and the best site for injection is the anterolateral aspect of the middle third of the thigh. In cases of refractory anaphylaxis, IV fluids and expert help should be sought.

Following stabilisation, patients may be given non-sedating oral antihistamines to manage persisting skin symptoms. It is important to refer all patients with a new diagnosis of anaphylaxis to a specialist allergy clinic and provide them with an adrenaline injector as an interim measure before the specialist assessment. Patients should also be prescribed two adrenaline auto-injectors and trained on how to use them. A risk-stratified approach to discharge should be taken, as biphasic reactions can occur in up to 20% of patients. The Resus Council UK recommends a fast-track discharge for patients who have had a good response to a single dose of adrenaline and complete resolution of symptoms, while those who require two doses of IM adrenaline or have a history of biphasic reaction should be observed for at least 12 hours following symptom resolution.

Dermatological Conditions and Their Distribution: Understanding the Diagnosis

When it comes to diagnosing skin conditions, the location and distribution of the rash or lesion are just as important as their appearance. For instance, a rash in the flexural regions of an adult patient, such as the popliteal region, is likely to be atopic dermatitis, especially if the patient has a history of asthma. Acute dermatitis typically presents with erythema, oedema, vesicles, and papules.

On the other hand, dermatitis herpetiformis, which is often associated with coeliac disease and malabsorption, presents with grouped vesicles and papules over the extensor surfaces of the elbows, knees, upper back, and buttocks. A rash limited to the popliteal region is unlikely to be dermatitis herpetiformis.

Lichen planus, characterized by flat-topped, pruritic, polygonal, red-to-violaceous papules or plaques, is mostly found on the wrists, ankles, or genitalia. Psoriasis, which presents with silvery, scaling, erythematous plaques, is primarily found on the extensor surfaces. Seborrhoeic dermatitis, which is found in the distribution of the sebaceous glands, such as the nasolabial folds, scalp, eyebrows, genitalia, and presternal regions, is unlikely to be the cause of a rash limited to the popliteal region.

In summary, understanding the distribution and location of skin lesions is crucial in making an accurate diagnosis of dermatological conditions.

Common Medical Tests and Their Uses

Immunoglobulin Measurement: This test measures the levels of immunoglobulin G (IgG), IgA, and IgM proteins in response to infection. Low levels of these proteins can lead to increased susceptibility to infections.

Flow Cytometry: This test is used to differentiate between different T cell populations and count the number of cells in a sample. It works by passing cells through a laser beam and analyzing the amount of light scatter to identify cell size and granularity.

Human Leukocyte Antigen (HLA) Typing: This test matches patients and donors for cord blood or bone marrow transplants by analyzing proteins used by the immune system to differentiate between self and non-self.

Patch Test: This test diagnoses delayed type IV hypersensitivity reactions by applying test substances to the skin and examining it for any inflammatory response.

Polymerase Chain Reaction: This test amplifies DNA segments for functional analysis of genes, diagnosis of hereditary diseases, and detection of infectious diseases.

For patients with diabetes who present with otitis externa, it is important to consider the possibility of malignant otitis externa, which is a severe bacterial infection that can spread to the bony ear canal and cause osteomyelitis. Pseudomonas aeruginosa is the most common cause of this condition, so treatment should involve coverage for this bacteria. Intravenous ciprofloxacin is the preferred antibiotic for this purpose. It is also important to note that diabetic patients with non-malignant otitis externa should also be treated with ciprofloxacin due to their increased risk of developing malignant otitis externa. Clarithromycin and flucloxacillin are not appropriate choices for this condition, and leaving the infection untreated can lead to serious complications.

Malignant Otitis Externa: A Rare but Serious Infection

Malignant otitis externa is a type of ear infection that is uncommon but can be serious. It is typically found in individuals who are immunocompromised, with 90% of cases occurring in diabetics. The infection starts in the soft tissues of the external auditory meatus and can progress to involve the soft tissues and bony ear canal, eventually leading to temporal bone osteomyelitis.

When diagnosing malignant otitis externa, doctors will typically perform a CT scan. Key features in a patient’s medical history include diabetes or immunosuppression, severe and unrelenting ear pain, temporal headaches, and purulent otorrhea. In some cases, patients may also experience dysphagia, hoarseness, and/or facial nerve dysfunction.

If a patient presents with non-resolving otitis externa and worsening pain, they should be referred urgently to an ear, nose, and throat specialist. Treatment typically involves intravenous antibiotics that cover pseudomonal infections.

Overall, while malignant otitis externa is rare, it is important to be aware of its symptoms and risk factors, particularly in immunocompromised individuals. Early diagnosis and treatment can help prevent the infection from progressing and causing more serious complications.

Treatment Options for Benign Prostatic Hypertrophy (BPH)

Benign prostatic hypertrophy (BPH) is a condition characterized by the proliferation of the cellular elements of the prostate, which can lead to chronic bladder outlet obstruction and a range of urinary symptoms. Treatment options for BPH depend on the severity of the symptoms and the size of the prostate.

The first-line drug of choice for men with moderate-to-severe lower urinary tract symptoms (LUTSs) is an α-blocker, such as alfuzosin, doxazosin, tamsulosin or terazosin. For men with larger prostates or higher prostate-specific antigen (PSA) levels, 5α-reductase inhibitors (e.g. finasteride) may also be offered. However, it is important to note that it may take up to 6 months for the patient to see an effect from this medication.

If storage symptoms persist after treatment with an α-blocker alone, anticholinergics such as oxybutynin may be added to the treatment plan. Surgery should only be considered for men with severe voiding symptoms that have not responded to drug therapy. First-line surgical options include transurethral resection of the prostate (TURP), monopolar transurethral vaporisation of the prostate (TUVP), or holmium laser enucleation of the prostate (HoLEP). Open prostatectomy should be reserved for men with very large prostates.

It is important to seek medical attention if conservative management options have failed or are not appropriate, as untreated BPH can lead to serious complications such as urinary retention, renal insufficiency, recurrent urinary tract infections, gross haematuria, and bladder calculi.

Urgent Hospital Admission Required for Erythrodermic Psoriasis

Erythrodermic psoriasis is a severe dermatological emergency that requires urgent hospital admission. This is evident in a patient who presents with a drop in blood pressure, tachycardia, borderline pyrexia, and rigors. While the patient’s psoriasis needs more intensive management, it is not appropriate to manage erythroderma in the community.

The treatment for erythrodermic psoriasis includes supportive care, such as intravenous fluids, cool, wet dressings, and a systemic agent. The choice of a systemic agent depends on the patient and may involve rapid-acting therapies like ciclosporin or slower agents like methotrexate. However, it is important to note that starting any systemic agent requires investigations, including baseline blood tests and a viral screen, to ensure it is not contraindicated.

It is crucial to differentiate erythrodermic psoriasis from other dermatological emergencies like Stevens-Johnson syndrome/toxic epidermal necrolysis (TEN), which is a severe drug reaction associated with amoxicillin and anti-epileptic therapies. However, in this case, the patient’s history features a slow deterioration of pre-existing psoriasis, and the rash is not desquamating, and there are no oral lesions. Therefore, hospital admission is required for erythrodermic psoriasis.

It is essential to avoid repeating phototherapy in a patient with erythrodermic psoriasis as it can worsen the condition. In a well patient, phototherapy would not be reattempted six months after a poor response, and an alternate approach would most likely be sought.

Bedside Abdominal Ultrasound for Ruptured Abdominal Aortic Aneurysm: Diagnosis and Management

This patient is likely experiencing a ruptured abdominal aortic aneurysm (AAA), a life-threatening medical emergency. Bedside abdominal ultrasound (US) is the best initial diagnostic test for ruling out AAA as a cause of abdominal or back pain, as it provides an instant, objective measurement of aortic diameter. An AAA is a dilatation of the abdominal aorta greater than 3 cm in diameter, with a significant risk of rupture at diameters greater than 5 cm. Risk factors for AAA include smoking and co-existing vascular disease. Symptoms of a ruptured AAA include pain, cardiovascular failure, and distal ischemia. Once diagnosed, a CT angiogram is the gold-standard imaging for planning surgery to repair the aneurysm. Endoscopic retrograde cholangiopancreatography and liver function tests are not indicated in this case, while serum amylase or lipase should be measured in all patients presenting with acute abdominal or upper back pain to exclude acute pancreatitis as a differential diagnosis.

Antipsychotics have the potential to cause acute dystonic reactions, including oculogyric crises. Symptoms may also include jaw spasms and tongue protrusion. Treatment typically involves administering IV procyclidine and discontinuing the medication responsible for the reaction. Akathisia is another potential side effect, characterized by restlessness and an inability to sit still. Tardive dyskinesia is a long-term side effect that can develop after years of antipsychotic use, resulting in involuntary facial movements such as grimacing, tongue protrusion, and lip smacking. Parkinsonism is a term used to describe antipsychotic side effects that mimic Parkinson’s disease, such as bradykinesia, cogwheel rigidity, and a shuffling gait.

Antipsychotics are a group of drugs used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. They are associated with extrapyramidal side-effects and hyperprolactinaemia, which are less common with atypical antipsychotics.

Extrapyramidal side-effects (EPSEs) are common with typical antipsychotics and include Parkinsonism, acute dystonia, sustained muscle contraction, akathisia, and tardive dyskinesia. The latter is a late onset of choreoathetoid movements that may be irreversible and occur in 40% of patients. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients, including an increased risk of stroke and venous thromboembolism. Other side-effects include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval.

Schizophrenia that is resistant to treatment can be very challenging to manage. Clozapine, an atypical antipsychotic, is one of the most effective drugs for this condition. However, it should only be used as a second or third line medication after trying at least two other antipsychotics for 6-8 weeks, with one of them being from the atypical class. Although clozapine is highly effective, it can cause serious side effects such as weight gain, excessive salivation, agranulocytosis, neutropenia, myocarditis, and arrhythmias. In this patient’s case, there is concern that he may be experiencing myocarditis due to his underlying psychiatric condition and potential use of clozapine.

Management of Schizophrenia: NICE Guidelines

Schizophrenia is a complex mental disorder that requires careful management. In 2009, the National Institute for Health and Care Excellence (NICE) published guidelines on the management of schizophrenia. According to these guidelines, oral atypical antipsychotics should be the first-line treatment for patients with schizophrenia. Additionally, cognitive behavioural therapy should be offered to all patients to help them manage their symptoms and improve their quality of life.

It is also important to pay close attention to cardiovascular risk-factor modification in patients with schizophrenia. This is because schizophrenic patients have high rates of cardiovascular disease, which is linked to antipsychotic medication and high smoking rates. Therefore, healthcare providers should work with patients to modify their lifestyle habits and reduce their risk of developing cardiovascular disease.

Overall, the NICE guidelines provide a comprehensive approach to managing schizophrenia. By following these guidelines, healthcare providers can help patients with schizophrenia achieve better outcomes and improve their overall health and well-being.

Long QT syndrome can be caused by hypokalaemia, which is an electrolyte imbalance that leads to a prolonged corrected QT interval on an ECG. This condition is often seen in young people and can present as cardiac syncope, tachyarrhythmias, palpitations, or cardiac arrest. Long QT syndrome can be inherited or acquired, with hypokalaemia being one of the acquired causes. Other causes include medications, CNS lesions, malnutrition, and hypothermia. It’s important to note that hypercalcaemia is associated with a shortened QT interval, not a prolonged one.

Understanding Long QT Syndrome

Long QT syndrome (LQTS) is a genetic condition that causes delayed repolarization of the ventricles, which can lead to ventricular tachycardia and sudden death. The most common types of LQTS are caused by defects in the alpha subunit of the slow delayed rectifier potassium channel. A normal corrected QT interval is less than 430 ms in males and 450 ms in females.

There are various causes of a prolonged QT interval, including congenital factors, drugs, and other medical conditions. Some drugs that can prolong the QT interval include amiodarone, tricyclic antidepressants, and selective serotonin reuptake inhibitors. Electrolyte imbalances, acute myocardial infarction, and subarachnoid hemorrhage can also cause a prolonged QT interval.

LQTS may be picked up on routine ECG or following family screening. The symptoms and events associated with LQTS can vary depending on the type of LQTS. Long QT1 is usually associated with exertional syncope, while Long QT2 is often associated with syncope following emotional stress or exercise. Long QT3 events often occur at night or at rest.

Management of LQTS involves avoiding drugs that prolong the QT interval and other precipitants if appropriate. Beta-blockers may be used, and in high-risk cases, implantable cardioverter defibrillators may be necessary. It is important to recognize and manage LQTS to prevent sudden cardiac death.

Patients who exhibit tachycardia along with symptoms of shock, syncope, myocardial ischaemia, or heart failure should be administered up to three synchronised DC shocks. Synchronised DC cardioversion is recommended for tachycardia with haemodynamic instability, signs of myocardial ischaemia, heart failure, or syncope. In this case, the patient is displaying signs of heart failure, and the elevated troponin levels are likely due to tachycardia rather than acute myocardial infarction (MI). Adenosine is not suitable for this situation as it is used to manage supraventricular tachycardia (SVT) that is not associated with shock, syncope, myocardial ischaemia, or heart failure. Amiodarone may be considered in atrial fibrillation with a fast ventricular response if synchronised DC cardioversion is ineffective, but it would not be the most appropriate management option at this time. IV metoprolol (or oral bisoprolol) is used in fast atrial fibrillation not associated with shock, syncope, myocardial ischaemia, or heart failure. However, since this patient is exhibiting signs of heart failure, this is not the correct course of action.

Management of Peri-Arrest Tachycardias

The Resuscitation Council (UK) guidelines for the management of peri-arrest tachycardias have been simplified in the 2015 update. The previous separate algorithms for broad-complex tachycardia, narrow complex tachycardia, and atrial fibrillation have been replaced by a unified treatment algorithm. After basic ABC assessment, patients are classified as stable or unstable based on the presence of adverse signs such as hypotension, pallor, sweating, confusion, or impaired consciousness. If any of these signs are present, synchronised DC shocks should be given, up to a maximum of three shocks.

The treatment following this is based on whether the QRS complex is narrow or broad and whether the rhythm is regular or irregular. For broad-complex tachycardia, a loading dose of amiodarone followed by a 24-hour infusion is given if the rhythm is regular. If the rhythm is irregular, expert help should be sought as it could be due to atrial fibrillation with bundle branch block, atrial fibrillation with ventricular pre-excitation, or torsade de pointes.

For narrow-complex tachycardia, vagal manoeuvres followed by IV adenosine are given if the rhythm is regular. If unsuccessful, atrial flutter is considered, and rate control is achieved with beta-blockers. If the rhythm is irregular, it is likely due to atrial fibrillation, and electrical or chemical cardioversion is considered if the onset is less than 48 hours. Beta-blockers are usually the first-line treatment for rate control unless contraindicated. The full treatment algorithm can be found on the Resuscitation Council website.

For the prophylactic management of migraines in a patient with a history of asthma, the recommended medication is topiramate. Propranolol is an alternative first-line option, but should be avoided in patients with asthma. Amitriptyline is a second-line drug for those who are not responsive to initial prophylactic treatment. Diclofenac is an NSAID used for acute management of migraines, while triptans like sumatriptan are used for acute treatment but not prophylaxis. It should be noted that topiramate is teratogenic and should be avoided in women of childbearing age.

Managing Migraines: Guidelines and Treatment Options

Migraines can be debilitating and affect a significant portion of the population. To manage migraines, it is important to understand the different treatment options available. According to the National Institute for Health and Care Excellence (NICE) guidelines, acute treatment for migraines involves a combination of an oral triptan and an NSAID or paracetamol. For young people aged 12-17 years, a nasal triptan may be preferred. If these measures are not effective, non-oral preparations of metoclopramide or prochlorperazine may be considered, along with a non-oral NSAID or triptan.

Prophylaxis should be given if patients are experiencing two or more attacks per month. NICE recommends topiramate or propranolol, depending on the patient’s preference, comorbidities, and risk of adverse events. Propranolol is preferred in women of childbearing age as topiramate may be teratogenic and reduce the effectiveness of hormonal contraceptives. Acupuncture and riboflavin may also be effective in reducing migraine frequency and intensity for some people. For women with predictable menstrual migraines, frovatriptan or zolmitriptan may be recommended as a type of mini-prophylaxis.

Specialists may consider other treatment options, such as candesartan or monoclonal antibodies directed against the calcitonin gene-related peptide (CGRP) receptor, like erenumab. However, pizotifen is no longer recommended due to common adverse effects like weight gain and drowsiness. It is important to exercise caution with young patients as acute dystonic reactions may develop. By following these guidelines and considering various treatment options, migraines can be effectively managed.

Management of Transient Ischaemic Attack (TIA)

Transient ischaemic attack (TIA) is a medical emergency that requires prompt management to prevent a subsequent stroke. Here are some management strategies for TIA:

Immediate administration of aspirin 300 mg and referral to the Stroke Clinic within 24 hours is recommended, unless contraindicated. Clopidogrel 75 mg once daily is the preferred secondary prevention following a stroke or TIA.

An outpatient magnetic resonance imaging (MRI) head scan may be considered to determine the territory of ischaemia, but only after assessment by a specialist at a TIA clinic.

Patients who have had a suspected TIA within the last week should be offered aspirin 300 mg at once and be seen by a stroke specialist within 24 hours. If the suspected TIA was more than one week ago, patients should be seen by a specialist within the next seven days.

Dual antiplatelet therapy with aspirin and clopidogrel may be considered for the first three months following a TIA or ischaemic stroke if the patient has severe symptomatic intracranial stenosis or for another condition such as acute coronary syndrome.

Management Strategies for Transient Ischaemic Attack (TIA)

Differential diagnosis of immunodeficiency in an adolescent with weight loss and recurrent infection

Malnutrition, primary immunodeficiency, cytomegalovirus (CMV) infection, human immunodeficiency virus (HIV) infection, and diabetes mellitus are among the possible causes of immunodeficiency in an adolescent with weight loss and recurrent infection. Malnutrition can suppress the immune system and is often associated with anorexia nervosa, which can be characterized by a very low body mass index (BMI), lanugo hair growth, hypothermia, bradycardia, and hypotension. Primary immunodeficiency syndromes, which are usually inherited as single-gene disorders, tend to present in infancy or early childhood with poor growth and weight gain and recurrent, prolonged, severe, or atypical infections. Cytomegalovirus (CMV) is a herpes virus that can cause serious complications in immunocompromised individuals or congenital cases, but is usually asymptomatic in immunocompetent individuals. Human immunodeficiency virus (HIV) infection can result in immunodeficiency by infecting and destroying CD4 cells, and should be suspected in individuals with prolonged, severe, or recurrent infections, particularly if they are a member of a high-risk group. Diabetes mellitus, especially type I, can also cause dysfunction of the immune system and increase the risk of infection. However, in an adolescent with a low BMI, type II diabetes would be very unlikely.

When hypertension is poorly controlled despite taking an ACE inhibitor and a calcium channel blocker, adding a thiazide-like diuretic is recommended. In patients with diabetic nephropathy, achieving tight blood pressure control is crucial. Although ACE inhibitors are the most evidence-based treatment, if blood pressure remains high, the NICE guidelines suggest adding a thiazide-based diuretic such as indapamide. It is important to avoid spironolactone and angiotensin II receptor blockers as they may increase the risk of hyperkalemia.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Ankylosing spondylitis is characterized by an early reduction in lateral flexion of the lumbar spine. Patients with this condition often experience a decrease in lumbar lordosis and an increase in thoracic kyphosis.

Ankylosing spondylitis is a type of spondyloarthropathy that is associated with HLA-B27. It is more commonly seen in young males, with a sex ratio of 3:1, and typically presents with lower back pain and stiffness that develops gradually. The stiffness is usually worse in the morning and improves with exercise, while pain at night may improve upon getting up. Clinical examination may reveal reduced lateral and forward flexion, as well as reduced chest expansion. Other features associated with ankylosing spondylitis include apical fibrosis, anterior uveitis, aortic regurgitation, Achilles tendonitis, AV node block, amyloidosis, cauda equina syndrome, and peripheral arthritis (more common in females).

Diagnosis and Investigation of Coeliac Disease

Coeliac disease is a possible diagnosis in patients presenting with chronic diarrhoea and steatorrhoea. The initial investigation of choice is the anti-tissue transglutaminase (anti-TTG) test, which has a sensitivity of over 96%. However, it is important to check immunoglobulin A (IgA) levels concurrently, as anti-TTG is an IgA antibody and may not be raised in the presence of IgA deficiency.

The treatment of choice for coeliac disease is a lifelong gluten-free diet, avoiding gluten-containing foods such as wheat, barley, rye, and oats. Patients with coeliac disease are at increased risk of small bowel lymphoma and oesophageal carcinoma over the long term.

While faecal fat estimation may be useful in estimating steatorrhoea, small bowel biopsy is the gold standard investigation for coeliac disease. However, this would not be the initial investigation of choice as it is invasive. An anti-TTG test is more sensitive and specific than an anti-gliadin test in untreated coeliac disease. Magnesium (Mg2+) levels may be abnormal in coeliac disease, but this would not be diagnostic and therefore not the first investigation of choice.

In summary, the diagnosis of coeliac disease requires a combination of clinical presentation, laboratory investigations, and small bowel biopsy if necessary. The anti-TTG test is the initial investigation of choice, and a gluten-free diet is the treatment of choice.

Experiencing a grief reaction is common after a significant loss, and it can manifest with physical and psychological symptoms that can last up to six months. It can be challenging to differentiate between depression and a typical grief reaction since they share similar symptoms. However, a regular grief reaction typically lasts less than six months, while depression can persist for a more extended period. Although she has brief visual hallucinations, psychosis is an incorrect diagnosis since she does not exhibit any other indications.

Grief is a natural response to the death of a loved one and does not always require medical intervention. However, understanding the potential stages of grief can help determine if a patient is experiencing a normal reaction or a more significant problem. The most common model of grief divides it into five stages: denial, anger, bargaining, depression, and acceptance. It is important to note that not all patients will experience all five stages. Atypical grief reactions are more likely to occur in women, sudden and unexpected deaths, problematic relationships before death, and lack of social support. Delayed grief, which occurs when grieving does not begin for more than two weeks, and prolonged grief, which is difficult to define but may last beyond 12 months, are features of atypical grief reactions.